Phase I trial of PCNU

L. A. Kalman, Richard J. Gralla, E. S. Casper, M. G. Kris, C. Gordon, T. M. Woodcock

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In a phase I trial, 28 patients with advanced solid tumors were given PCNU daily for 5 days by iv infusion over 20 minutes at 6-week intervals. The total dose for each course ranged from 25 to 150 mg/m2 in six escalation steps. Myelosuppression was dose-limiting, with a platelet count depression regularly observed at doses of ≥ 82.5 mg/m2. Leukopenia occurred only at higher doses. Nausea was uncommon, and vomiting did not occur. There were no adverse drug-related effects on renal or hepatic function. No antitumor activity was observed. A dose range of 100-125 mg/m2 iv for each 5-day course (20-25 mg/m2/day) is recommended for phase II studies.

Original languageEnglish (US)
Pages (from-to)1027-1029
Number of pages3
JournalCancer Treatment Reports
Volume67
Issue number11
StatePublished - 1983
Externally publishedYes

Fingerprint

Leukopenia
Platelet Count
Nausea
Vomiting
Kidney
Liver
Pharmaceutical Preparations
Neoplasms
1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidinyl)-1-nitrosourea

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kalman, L. A., Gralla, R. J., Casper, E. S., Kris, M. G., Gordon, C., & Woodcock, T. M. (1983). Phase I trial of PCNU. Cancer Treatment Reports, 67(11), 1027-1029.

Phase I trial of PCNU. / Kalman, L. A.; Gralla, Richard J.; Casper, E. S.; Kris, M. G.; Gordon, C.; Woodcock, T. M.

In: Cancer Treatment Reports, Vol. 67, No. 11, 1983, p. 1027-1029.

Research output: Contribution to journalArticle

Kalman, LA, Gralla, RJ, Casper, ES, Kris, MG, Gordon, C & Woodcock, TM 1983, 'Phase I trial of PCNU', Cancer Treatment Reports, vol. 67, no. 11, pp. 1027-1029.
Kalman LA, Gralla RJ, Casper ES, Kris MG, Gordon C, Woodcock TM. Phase I trial of PCNU. Cancer Treatment Reports. 1983;67(11):1027-1029.
Kalman, L. A. ; Gralla, Richard J. ; Casper, E. S. ; Kris, M. G. ; Gordon, C. ; Woodcock, T. M. / Phase I trial of PCNU. In: Cancer Treatment Reports. 1983 ; Vol. 67, No. 11. pp. 1027-1029.
@article{27ff6b566e734207847860f08a63070a,
title = "Phase I trial of PCNU",
abstract = "In a phase I trial, 28 patients with advanced solid tumors were given PCNU daily for 5 days by iv infusion over 20 minutes at 6-week intervals. The total dose for each course ranged from 25 to 150 mg/m2 in six escalation steps. Myelosuppression was dose-limiting, with a platelet count depression regularly observed at doses of ≥ 82.5 mg/m2. Leukopenia occurred only at higher doses. Nausea was uncommon, and vomiting did not occur. There were no adverse drug-related effects on renal or hepatic function. No antitumor activity was observed. A dose range of 100-125 mg/m2 iv for each 5-day course (20-25 mg/m2/day) is recommended for phase II studies.",
author = "Kalman, {L. A.} and Gralla, {Richard J.} and Casper, {E. S.} and Kris, {M. G.} and C. Gordon and Woodcock, {T. M.}",
year = "1983",
language = "English (US)",
volume = "67",
pages = "1027--1029",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Phase I trial of PCNU

AU - Kalman, L. A.

AU - Gralla, Richard J.

AU - Casper, E. S.

AU - Kris, M. G.

AU - Gordon, C.

AU - Woodcock, T. M.

PY - 1983

Y1 - 1983

N2 - In a phase I trial, 28 patients with advanced solid tumors were given PCNU daily for 5 days by iv infusion over 20 minutes at 6-week intervals. The total dose for each course ranged from 25 to 150 mg/m2 in six escalation steps. Myelosuppression was dose-limiting, with a platelet count depression regularly observed at doses of ≥ 82.5 mg/m2. Leukopenia occurred only at higher doses. Nausea was uncommon, and vomiting did not occur. There were no adverse drug-related effects on renal or hepatic function. No antitumor activity was observed. A dose range of 100-125 mg/m2 iv for each 5-day course (20-25 mg/m2/day) is recommended for phase II studies.

AB - In a phase I trial, 28 patients with advanced solid tumors were given PCNU daily for 5 days by iv infusion over 20 minutes at 6-week intervals. The total dose for each course ranged from 25 to 150 mg/m2 in six escalation steps. Myelosuppression was dose-limiting, with a platelet count depression regularly observed at doses of ≥ 82.5 mg/m2. Leukopenia occurred only at higher doses. Nausea was uncommon, and vomiting did not occur. There were no adverse drug-related effects on renal or hepatic function. No antitumor activity was observed. A dose range of 100-125 mg/m2 iv for each 5-day course (20-25 mg/m2/day) is recommended for phase II studies.

UR - http://www.scopus.com/inward/record.url?scp=0021041079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021041079&partnerID=8YFLogxK

M3 - Article

C2 - 6315229

AN - SCOPUS:0021041079

VL - 67

SP - 1027

EP - 1029

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 11

ER -